in silico methods in fragment-based drug design — a Protein Kinase B case study

webinar

Wed, 28 Jan 2015, 19:00 CET (Berlin)

Dr. Alastair Donald, BioSolveIT GmbH, St. Augustin, Germany

in silico methods in fragment-based drug design — a Protein Kinase B case study

Computational tools are invaluable in the process of identifying high-quality fragment hits. In this one hour BioSolveIT webinar you will learn how to fast-track your fragment hit discovery using our cutting edge in silico solutions using Protein Kinase B as an example.

By the end you will appreciate how our suite of SBDD tools can enrich your work life, enhance your productivity and assist in the identification of potent, selective and synthetically accessible lead-like molecules.

So, if you are interested in

  • enriching your screening collection with potent and selective fragments
  • intelligently selecting which commercially available analogs to purchase
  • deciding which analogs to prioritize for synthesis
  • saving time and money by focusing on the most promising ideas

watch the video live recording below.

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on